CervoMed (CRVO) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
INmune Bio (INMB) has outperformed CervoMed (CRVO) over the past year, losing 9.0% versus a loss of 63.1%. Over five years, INMB leads with a -90.2% price change compared with -90.9% for CRVO. INmune Bio is the larger company by market cap ($51.2 million vs $49.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVO | INMB |
|---|---|---|
| Share price | $3.24 | $1.85 |
| Market cap | $48.99M | $51.21M |
| 1-day change | -1.20% | +0.82% |
| YTD return | -58.48% | +17.31% |
| 1-year return | -63.15% | -8.96% |
| 5-year return | -90.89% | -90.17% |
| EPS (TTM) | $-3.21 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.00 | $2.60 |
| 52-week low | $2.13 | $1.09 |
| Distance from 52-week high | -67.59% | -29.04% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +375.22% | +279.40% |
| Average volume | 339.08K | 402.12K |
| Shares outstanding | 15.12M | 27.75M |
| Employees | 15 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed CRVO by 54.2 percentage points over the past year.
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
CRVO vs INMB FAQ
Which is bigger, CervoMed or INmune Bio?
INmune Bio (INMB) is larger, with a market capitalization of $51.21M compared with $48.99M for CervoMed (CRVO).
Which stock has performed better over the past year, CRVO or INMB?
INMB returned -8.96% over the past 12 months, compared with -63.15% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are CervoMed and INmune Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for CervoMed and Biotechnology: Biological Products (No Diagnostic Substances) for INmune Bio.